Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio's Abecma in Relapsed or Refractory Multiple Myeloma
Six-and-a-Half-Year Outcomes for Opdivo in Combination with Yervoy Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
Opdivo Plus Yervoy with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial
Bristol Myers Squibb Announces LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination Significantly Improves Progression-Free Survival vs. Opdivo in Patients with Previously Untreated Metastatic or Unresectable Melanoma
Four-Year Data from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy in Patients with Non-Small Cell Lung Cancer with PD-L1 Expression ?1%
Psychedelics Investing EBON, DOX & SHRMF Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm
Medical Device Investing Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center
Cannabis Investing Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products
AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses
